Trial Outcomes & Findings for Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity (NCT NCT04114903)
NCT ID: NCT04114903
Last Updated: 2026-08-06
Results Overview
Change in Circulating Levels of Cytokines (TNF-α, IL-6, IL-1β, IL-12, IFNG, and IL-4). Results are reported as a composite score of TNF-α, IL-6, IL-1β, IL-12, IFNG, and IL-4
COMPLETED
233 participants
Study A: Difference between cytokines at baseline and cytokines one week later after acute use of cannabis product. Study B: Change from baseline to four weeks
2026-08-06
Participant Flow
Participant milestones
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, THC
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Non-use
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants were asked not to use cannabis for four weeks.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
34
|
28
|
46
|
9
|
47
|
41
|
28
|
|
Overall Study
Completed Baseline Appointment
|
34
|
28
|
46
|
9
|
47
|
41
|
28
|
|
Overall Study
COMPLETED
|
29
|
25
|
44
|
9
|
43
|
36
|
28
|
|
Overall Study
NOT COMPLETED
|
5
|
3
|
2
|
0
|
4
|
5
|
0
|
Reasons for withdrawal
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, THC
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Non-use
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants were asked not to use cannabis for four weeks.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
5
|
3
|
2
|
0
|
4
|
5
|
0
|
Baseline Characteristics
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
Baseline characteristics by cohort
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, THC
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Non-use
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Total
n=233 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
29.62 Years
STANDARD_DEVIATION 5.59 • n=20 Participants
|
30.07 Years
STANDARD_DEVIATION 5.90 • n=20 Participants
|
29.41 Years
STANDARD_DEVIATION 5.14 • n=40 Participants
|
29.89 Years
STANDARD_DEVIATION 6.55 • n=6 Participants
|
29.57 Years
STANDARD_DEVIATION 4.67 • n=7 Participants
|
30.20 Years
STANDARD_DEVIATION 5.17 • n=13 Participants
|
29.25 Years
STANDARD_DEVIATION 7.03 • n=6 Participants
|
29.7 Years
STANDARD_DEVIATION 5.5 • n=6 Participants
|
|
Sex/Gender, Customized
Sex · Male
|
13 Participants
n=20 Participants
|
12 Participants
n=20 Participants
|
20 Participants
n=40 Participants
|
4 Participants
n=6 Participants
|
31 Participants
n=7 Participants
|
27 Participants
n=13 Participants
|
12 Participants
n=6 Participants
|
119 Participants
n=6 Participants
|
|
Sex/Gender, Customized
Sex · Female
|
20 Participants
n=20 Participants
|
16 Participants
n=20 Participants
|
25 Participants
n=40 Participants
|
5 Participants
n=6 Participants
|
15 Participants
n=7 Participants
|
14 Participants
n=13 Participants
|
15 Participants
n=6 Participants
|
110 Participants
n=6 Participants
|
|
Sex/Gender, Customized
Sex · Other
|
1 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=40 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=13 Participants
|
1 Participants
n=6 Participants
|
4 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
3 Participants
n=40 Participants
|
1 Participants
n=6 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=13 Participants
|
4 Participants
n=6 Participants
|
14 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=40 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
29 Participants
n=20 Participants
|
27 Participants
n=20 Participants
|
39 Participants
n=40 Participants
|
7 Participants
n=6 Participants
|
40 Participants
n=7 Participants
|
37 Participants
n=13 Participants
|
24 Participants
n=6 Participants
|
203 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=13 Participants
|
0 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
1 Participants
n=20 Participants
|
3 Participants
n=40 Participants
|
1 Participants
n=6 Participants
|
4 Participants
n=7 Participants
|
1 Participants
n=13 Participants
|
0 Participants
n=6 Participants
|
10 Participants
n=6 Participants
|
|
Body Mass Index (BMI)
|
23.71 kg/m2
STANDARD_DEVIATION 3.00 • n=20 Participants
|
27.07 kg/m2
STANDARD_DEVIATION 5.67 • n=20 Participants
|
23.82 kg/m2
STANDARD_DEVIATION 3.17 • n=40 Participants
|
25.10 kg/m2
STANDARD_DEVIATION 9.16 • n=6 Participants
|
24.68 kg/m2
STANDARD_DEVIATION 4.32 • n=7 Participants
|
24.25 kg/m2
STANDARD_DEVIATION 5.80 • n=13 Participants
|
24.77 kg/m2
STANDARD_DEVIATION 3.75 • n=6 Participants
|
24.61 kg/m2
STANDARD_DEVIATION 4.69 • n=6 Participants
|
|
Sleep Quality (Pittsburgh Sleep Quality Index Item 15)
|
0.88 units on a scale
STANDARD_DEVIATION 0.73 • n=20 Participants
|
0.82 units on a scale
STANDARD_DEVIATION 0.67 • n=20 Participants
|
0.98 units on a scale
STANDARD_DEVIATION 0.61 • n=40 Participants
|
0.89 units on a scale
STANDARD_DEVIATION 0.60 • n=6 Participants
|
0.91 units on a scale
STANDARD_DEVIATION 0.54 • n=7 Participants
|
0.98 units on a scale
STANDARD_DEVIATION 0.58 • n=13 Participants
|
0.96 units on a scale
STANDARD_DEVIATION 0.58 • n=6 Participants
|
0.91 units on a scale
STANDARD_DEVIATION 0.62 • n=6 Participants
|
|
Alcohol Use (Quantity x Frequency)
|
16.90 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 12.63 • n=20 Participants
|
13.59 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 6.43 • n=20 Participants
|
14.29 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 13.59 • n=40 Participants
|
14.14 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 15.58 • n=6 Participants
|
23.47 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 24.25 • n=7 Participants
|
21.74 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 18.23 • n=13 Participants
|
10.18 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 10.49 • n=6 Participants
|
17.32 Monthly total of avg drinks/drinking day
STANDARD_DEVIATION 16.65 • n=6 Participants
|
PRIMARY outcome
Timeframe: Study A: Difference between cytokines at baseline and cytokines one week later after acute use of cannabis product. Study B: Change from baseline to four weeksChange in Circulating Levels of Cytokines (TNF-α, IL-6, IL-1β, IL-12, IFNG, and IL-4). Results are reported as a composite score of TNF-α, IL-6, IL-1β, IL-12, IFNG, and IL-4
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Markers of Inflammation
|
1.11 pg/mL
Standard Deviation 0.58
|
1.53 pg/mL
Standard Deviation 0.81
|
2.74 pg/mL
Standard Deviation 3.70
|
3.18 pg/mL
Standard Deviation 3.71
|
1.04 pg/mL
Standard Deviation 0.54
|
1.54 pg/mL
Standard Deviation 1.14
|
1.05 pg/mL
Standard Deviation 0.34
|
1.10 pg/mL
Standard Deviation 0.42
|
1.04 pg/mL
Standard Deviation 0.50
|
1.10 pg/mL
Standard Deviation 0.45
|
1.01 pg/mL
Standard Deviation 0.52
|
1.17 pg/mL
Standard Deviation 0.77
|
1.57 pg/mL
Standard Deviation 0.67
|
1.64 pg/mL
Standard Deviation 0.75
|
PRIMARY outcome
Timeframe: Study A: Baseline versus after acute use one week later of cannabis product. Study B: The two tests will be separated by four weeksCalculation of Insulin Sensitivity using changes in fasting plasma glucose (FPG) and fasting plasma insulin (FPI). Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes after ingestion of 75 grams oral glucose during oral glucose tolerance test (OGTT). Values across the timepoints were combined to create a Matsuda Index score as follows: 10000/sqrt ((FPG X FPI) X (Mean OGTT glucose concentration X Mean OGTT insulin concentration)). Higher scores mean higher sensitive to insulin and that your body more efficiently clears glucose from your bloodstream, thus higher scores are better.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change in Matsuda Index of Insulin Sensitivity
|
14.07 Index scores
Standard Deviation 7.65
|
15.52 Index scores
Standard Deviation 7.88
|
13.64 Index scores
Standard Deviation 8.70
|
12.89 Index scores
Standard Deviation 8.79
|
13.28 Index scores
Standard Deviation 6.77
|
13.40 Index scores
Standard Deviation 5.75
|
11.79 Index scores
Standard Deviation 6.27
|
12.51 Index scores
Standard Deviation 6.59
|
12.68 Index scores
Standard Deviation 7.43
|
11.29 Index scores
Standard Deviation 7.24
|
15.56 Index scores
Standard Deviation 8.52
|
14.98 Index scores
Standard Deviation 8.01
|
11.79 Index scores
Standard Deviation 7.94
|
12.24 Index scores
Standard Deviation 6.70
|
PRIMARY outcome
Timeframe: Study A: Baseline versus one week later after acute use of cannabis product. Study B: The two tests will be separated by four weeksChange in glucose over time after ingestion of 75 grams oral glucose measured during during oral glucose tolerance test (OGTT). Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes and averaged across these timepoints for a mean score.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change in Plasma Glucose
|
101.85 mg/dL
Standard Deviation 21.82
|
110.15 mg/dL
Standard Deviation 21.66
|
104.24 mg/dL
Standard Deviation 25.25
|
114.78 mg/dL
Standard Deviation 27.44
|
104.37 mg/dL
Standard Deviation 22.97
|
117.04 mg/dL
Standard Deviation 22.98
|
97.50 mg/dL
Standard Deviation 10.50
|
99.44 mg/dL
Standard Deviation 15.94
|
118.61 mg/dL
Standard Deviation 23.69
|
118.01 mg/dL
Standard Deviation 18.77
|
106.47 mg/dL
Standard Deviation 15.34
|
102.77 mg/dL
Standard Deviation 15.54
|
109.90 mg/dL
Standard Deviation 20.80
|
98.86 mg/dL
Standard Deviation 24.39
|
PRIMARY outcome
Timeframe: Study A: Baseline versus one week later after acute use of cannabis product. Study B: Baseline versus four weeks laterChange in insulin over time after ingestion of 75 grams oral glucose measured during OGTT. Measurements are collected on venous blood samples at 0, 30, 60, 90, and 120 minutes and averaged across these timepoints for a mean score.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Change in Plasma Insulin
|
25.37 pmol/L
Standard Deviation 12.78
|
26.40 pmol/L
Standard Deviation 17.22
|
32.34 pmol/L
Standard Deviation 30.87
|
37.35 pmol/L
Standard Deviation 33.86
|
24.17 pmol/L
Standard Deviation 14.19
|
27.53 pmol/L
Standard Deviation 21.29
|
28.18 pmol/L
Standard Deviation 13.14
|
28.89 pmol/L
Standard Deviation 12.42
|
28.04 pmol/L
Standard Deviation 19.97
|
30.42 pmol/L
Standard Deviation 18.37
|
20.77 pmol/L
Standard Deviation 10.55
|
21.80 pmol/L
Standard Deviation 11.97
|
37.86 pmol/L
Standard Deviation 29.57
|
29.05 pmol/L
Standard Deviation 16.10
|
SECONDARY outcome
Timeframe: Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baselineInterviewer administered assessment of number of minutes of moderate to vigorous physical activity over the previous seven days. Scores are reported as total minutes in the last week summed across moderate, hard, and very hard activity levels.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Stanford Seven-Day Physical Activity Recall (PAR)
|
344.12 Total activity minutes/past week
Standard Deviation 230.97
|
304.48 Total activity minutes/past week
Standard Deviation 241.07
|
509.39 Total activity minutes/past week
Standard Deviation 389.60
|
357.28 Total activity minutes/past week
Standard Deviation 258.63
|
408.30 Total activity minutes/past week
Standard Deviation 304.30
|
436.36 Total activity minutes/past week
Standard Deviation 348.88
|
463.89 Total activity minutes/past week
Standard Deviation 399.43
|
529.44 Total activity minutes/past week
Standard Deviation 477.17
|
492.57 Total activity minutes/past week
Standard Deviation 525.58
|
341.28 Total activity minutes/past week
Standard Deviation 274.51
|
575.07 Total activity minutes/past week
Standard Deviation 589.44
|
510.17 Total activity minutes/past week
Standard Deviation 594.33
|
406.50 Total activity minutes/past week
Standard Deviation 467.66
|
320.79 Total activity minutes/past week
Standard Deviation 201.99
|
SECONDARY outcome
Timeframe: Study A: Baseline only Study B: Baseline to four weeks following baselinePittsburgh Sleep Quality Index: Measurement of the quality and patterns of sleep from poor to good measuring seven domains (e.g., latency, duration, disturbances) over the last 2 weeks. Participants' scores are reported as a global score of the summed seven component scores together ranging from 0 to 21, where higher scores indicate worse sleep and a global score of 5 or above indicates poor sleep quality.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sleep Quality
|
5.21 Units on a scale
Standard Deviation 3.37
|
4.88 Units on a scale
Standard Deviation 3.04
|
4.84 Units on a scale
Standard Deviation 3.06
|
4.57 Units on a scale
Standard Deviation 2.37
|
4.00 Units on a scale
Standard Deviation 1.51
|
5.33 Units on a scale
Standard Deviation 2.98
|
5.12 Units on a scale
Standard Deviation 2.68
|
5.94 Units on a scale
Standard Deviation 3.34
|
4.97 Units on a scale
Standard Deviation 3.48
|
3.85 Units on a scale
Standard Deviation 2.13
|
3.69 Units on a scale
Standard Deviation 2.62
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline only. Study B: Baseline and four weeks following baselineTimes per day of cannabis flower use from 0 to 6. Includes all participants in Study A and only cannabis users in Study B.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Marijuana Consumption Questionnaire
|
1.06 Cannabis use times/day
Standard Deviation 0.24
|
1.00 Cannabis use times/day
Standard Deviation 0.00
|
1.04 Cannabis use times/day
Standard Deviation 0.21
|
2.22 Cannabis use times/day
Standard Deviation 1.79
|
1.78 Cannabis use times/day
Standard Deviation 1.09
|
2.98 Cannabis use times/day
Standard Deviation 1.74
|
2.74 Cannabis use times/day
Standard Deviation 1.55
|
2.12 Cannabis use times/day
Standard Deviation 1.45
|
2.26 Cannabis use times/day
Standard Deviation 1.36
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline only. Study B: Baseline and four weeks following baselineThis is a self-report scale based on DSM-5 criteria to assess dependence and other problems related to the use of cannabis. Scores are reported as a sum across the 11 items with yes/no options, ranging from 0 to 11, with higher scores indicating more dependence symptoms. Includes all participants in Study A and only cannabis users in Study B.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Marijuana Dependence Scale
|
0.35 Scores on a scale
Standard Deviation 0.98
|
0.46 Scores on a scale
Standard Deviation 1.23
|
0.15 Scores on a scale
Standard Deviation 0.42
|
1.67 Scores on a scale
Standard Deviation 1.66
|
1.56 Scores on a scale
Standard Deviation 1.51
|
2.30 Scores on a scale
Standard Deviation 2.15
|
2.00 Scores on a scale
Standard Deviation 2.15
|
1.68 Scores on a scale
Standard Deviation 1.90
|
1.61 Scores on a scale
Standard Deviation 1.90
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Assessed at follow-up, one week following baseline. Study B: Assessed at follow-up, four weeks following baseline.A 15-item scale used to collect information on withdrawal symptoms that participants may be experiencing due to the lack of use of marijuana. Options range from 0 (none) to 3 (severe) for each question and are summed to create a final score ranging from 0 to 45. Includes all participants in Study A and only cannabis users in Study B.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=41 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Marijuana Withdrawal Checklist
|
2.69 Scores on a scale
Standard Deviation 5.46
|
2.48 Scores on a scale
Standard Deviation 3.31
|
1.42 Scores on a scale
Standard Deviation 2.54
|
4.56 Scores on a scale
Standard Deviation 5.10
|
6.30 Scores on a scale
Standard Deviation 6.12
|
4.97 Scores on a scale
Standard Deviation 5.88
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline only. Study B: Baseline and four weeks following baselineStandardized assessment of the extent of alcohol use and problems related to alcohol use. Scores are summed and range from 0 to 40 with higher scores indicating more hazardous alcohol use.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
The Alcohol Use Disorder Identification Test (AUDIT)
|
3.53 Units on a scale
Standard Deviation 2.93
|
3.29 Units on a scale
Standard Deviation 2.95
|
3.17 Units on a scale
Standard Deviation 2.29
|
2.78 Units on a scale
Standard Deviation 1.72
|
3.00 Units on a scale
Standard Deviation 1.73
|
3.72 Units on a scale
Standard Deviation 3.13
|
4.28 Units on a scale
Standard Deviation 2.87
|
4.10 Units on a scale
Standard Deviation 2.31
|
4.56 Units on a scale
Standard Deviation 2.60
|
2.29 Units on a scale
Standard Deviation 1.65
|
2.32 Units on a scale
Standard Deviation 1.83
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline only. Study B: Baseline and four weeks following baselineCalendar-based assessment of daily substance use for the 30 days prior to the baseline session for both studies. The average days of smoked cannabis use in the last 30 days are reported.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Timeline Follow-Back of Substance Use
|
0.09 Cannabis use days/month
Standard Deviation 0.38
|
0.07 Cannabis use days/month
Standard Deviation 0.38
|
0.04 Cannabis use days/month
Standard Deviation 0.21
|
19.33 Cannabis use days/month
Standard Deviation 8.00
|
16.89 Cannabis use days/month
Standard Deviation 8.25
|
22.68 Cannabis use days/month
Standard Deviation 7.33
|
23.95 Cannabis use days/month
Standard Deviation 7.41
|
21.17 Cannabis use days/month
Standard Deviation 7.74
|
20.97 Cannabis use days/month
Standard Deviation 8.36
|
0.00 Cannabis use days/month
Standard Deviation 0.00
|
0.00 Cannabis use days/month
Standard Deviation 0.00
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline only. Study B: Baseline and four weeks following baselineThe SF-12 Health Survey is a 12-item questionnaire used to assess general health and well-being and includes domains of physical functioning, role-physical, pain, general health, vitality, social functioning, role-emotional and mental health. Only the mental component was analyzed. Scores are calculated using a weighted algorithm with scores ranging from 0 to 100; scores greater than 50 meaning better than average health and scores worse than 50 meaning worse than average health.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SF-12 Health Survey
|
47.33 Units on a scale
Standard Deviation 10.30
|
50.16 Units on a scale
Standard Deviation 7.39
|
46.15 Units on a scale
Standard Deviation 10.69
|
49.36 Units on a scale
Standard Deviation 6.39
|
51.50 Units on a scale
Standard Deviation 6.64
|
46.14 Units on a scale
Standard Deviation 9.89
|
47.48 Units on a scale
Standard Deviation 9.01
|
44.84 Units on a scale
Standard Deviation 10.84
|
45.87 Units on a scale
Standard Deviation 11.23
|
52.28 Units on a scale
Standard Deviation 6.25
|
49.38 Units on a scale
Standard Deviation 11.42
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baselineInterviewer administered recall measure developed by the University of Minnesota Nutrition Coordinating Center (NCC), that facilitates the standardized collection of 24-hour dietary recall data. Healthy Eating Index (HEI) total scores are reported for each participant, which is a measure of healthy eating on a scale of 0 (poor eating) to 100 (very healthy eating). Scores above 80 indicate a good diet, and scores below 80 indicate a diet in need of improvement.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nutrition Data System for Research 24-Hour Dietary Recall
|
55.14 Scale scores
Standard Deviation 15.00
|
53.62 Scale scores
Standard Deviation 15.88
|
57.44 Scale scores
Standard Deviation 14.36
|
54.58 Scale scores
Standard Deviation 16.68
|
55.44 Scale scores
Standard Deviation 14.79
|
51.38 Scale scores
Standard Deviation 16.21
|
53.99 Scale scores
Standard Deviation 17.16
|
46.92 Scale scores
Standard Deviation 13.71
|
52.29 Scale scores
Standard Deviation 16.01
|
49.80 Scale scores
Standard Deviation 14.35
|
53.04 Scale scores
Standard Deviation 14.65
|
57.86 Scale scores
Standard Deviation 14.12
|
54.97 Scale scores
Standard Deviation 13.49
|
52.98 Scale scores
Standard Deviation 17.63
|
SECONDARY outcome
Timeframe: Study A: Baseline and one week following baseline Study B: Baseline and four weeks following baselineSelf-report measure of a single item comprising six descriptive categories ranging from inactive (1) to very active (6).
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=34 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
n=46 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
n=9 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
n=47 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
n=41 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
n=28 Participants
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Stanford Leisure-Time Activity Categorical Item (L-Cat)
|
4.09 Units on a scale
Standard Deviation 1.33
|
3.69 Units on a scale
Standard Deviation 1.17
|
3.96 Units on a scale
Standard Deviation 1.29
|
3.64 Units on a scale
Standard Deviation 1.04
|
3.93 Units on a scale
Standard Deviation 1.32
|
3.72 Units on a scale
Standard Deviation 1.24
|
3.89 Units on a scale
Standard Deviation 1.17
|
3.78 Units on a scale
Standard Deviation 1.09
|
3.53 Units on a scale
Standard Deviation 1.32
|
3.49 Units on a scale
Standard Deviation 1.20
|
3.76 Units on a scale
Standard Deviation 1.30
|
3.83 Units on a scale
Standard Deviation 1.42
|
4.25 Units on a scale
Standard Deviation 1.27
|
3.93 Units on a scale
Standard Deviation 1.30
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Study B only: Daily for four weeks between baseline and second study visitDaily surveys sent to Study B participants during the four-week period between study visits querying alcohol use. This is reported as average number of drinks/day of alcohol use.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=41 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Daily Online Survey of Alcohol Use
|
1.83 Avg drinks/drinking day
Standard Deviation 0.49
|
2.22 Avg drinks/drinking day
Standard Deviation 1.03
|
2.09 Avg drinks/drinking day
Standard Deviation 0.73
|
1.82 Avg drinks/drinking day
Standard Deviation 0.79
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Study B only: Daily for four weeks between baseline and second study visitDaily surveys sent to Study B participants during the four-week period between study visits querying minutes of exercise. This is reported as average minutes/day on exercise days.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=41 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Daily Only Survey of Exercise
|
50.44 Avg minutes of exercise/exercise day
Standard Deviation 24.49
|
50.20 Avg minutes of exercise/exercise day
Standard Deviation 35.16
|
57.97 Avg minutes of exercise/exercise day
Standard Deviation 33.83
|
50.35 Avg minutes of exercise/exercise day
Standard Deviation 25.82
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Study B only: Daily for four weeks between baseline and second study visitDaily surveys sent to Study B participants during the four-week period between study visits querying consumption of fruits and vegetables. This is reported as average servings/day on fruit/vegetable consumption days.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=41 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Daily Only Survey of Fruit/Vegetable Consumption
|
2.69 Avg servings/fruit and veg day
Standard Deviation 1.63
|
2.71 Avg servings/fruit and veg day
Standard Deviation 1.32
|
3.32 Avg servings/fruit and veg day
Standard Deviation 2.65
|
3.44 Avg servings/fruit and veg day
Standard Deviation 2.96
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Study B only: Daily for four weeks between baseline and second study visitDaily surveys sent to Study B participants during the four-week period between study visits querying amount of cannabis used. This is reported as average grams/cannabis use day.
Outcome measures
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD -- Baseline
n=9 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, CBD -- Follow-up
n=47 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC -- Baseline
n=41 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC -- Follow-up
n=28 Participants
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 1 week after baseline.
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Baseline
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD -- Follow-up
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 1 week after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use CBD (\~14% CBD/0% THC).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC (\~14% THC/0% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who chose to use cannabis were asked to purchase and use THC+CBD (\~7% THC/7% CBD).
Follow-up was 4 weeks after baseline.
|
Study B: Non-use -- Baseline
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
Study B: Non-use -- Follow-up
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
Follow-up was 4 weeks after baseline.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Daily Online Survey on Cannabis Use
|
0.17 Avg grams/cannabis use day
Standard Deviation 0.27
|
0.40 Avg grams/cannabis use day
Standard Deviation 0.56
|
0.28 Avg grams/cannabis use day
Standard Deviation 0.51
|
0.00 Avg grams/cannabis use day
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Study A: Single Use of Cannabis Flower Product, CBD
Study A: Single Use of Cannabis Flower Product, THC
Study A: Single Use of Cannabis Flower Product, THC+CBD
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD
Study B: Ad Libitum Cannabis Use for Four Weeks, THC
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD
Study B: Non-use
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Study A: Single Use of Cannabis Flower Product, CBD
n=34 participants at risk
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study A: Single Use of Cannabis Flower Product, THC
n=28 participants at risk
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study A: Single Use of Cannabis Flower Product, THC+CBD
n=46 participants at risk
Adults balanced across the weight spectrum who have tried cannabis at least once with no negative reaction but are not regular users. Participants are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, CBD
n=9 participants at risk
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use CBD (\~14% CBD/0% THC).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC
n=47 participants at risk
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC (\~14% THC/0% CBD).
|
Study B: Ad Libitum Cannabis Use for Four Weeks, THC+CBD
n=41 participants at risk
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants who choose to use cannabis are asked to purchase and use THC+CBD (\~7% THC/7% CBD).
|
Study B: Non-use
n=28 participants at risk
Sample of current cannabis users and non-users balanced across the weight spectrum who are matched on age, gender, BMI and physical activity. Participants in the non-use group did not use cannabis.
|
|---|---|---|---|---|---|---|---|
|
General disorders
Fainting during blood draw
|
2.9%
1/34 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
2.2%
1/46 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/9 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
2.1%
1/47 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/41 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
7.1%
2/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
|
General disorders
Lightheadedness
|
0.00%
0/34 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
2.2%
1/46 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/9 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
6.4%
3/47 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
4.9%
2/41 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
7.1%
2/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/34 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
3.6%
1/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/46 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
—
0/0 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/47 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
0.00%
0/41 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
3.6%
1/28 • From baseline until follow-up (1 week for Study A, 4 for Study B)
Mortality, serious adverse events, and other adverse events were all monitored.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place